Please ensure Javascript is enabled for purposes of website accessibility

What You'll Want to Know About Cantel Medical's Mixed Q3 Results

By Keith Speights – Jun 4, 2019 at 3:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The medical products company beat Wall Street revenue estimates. But its bottom line was a different story.

Cantel Medical (CMD) reported mixed results when it announced its second-quarter results at the end of February. Revenue rose by 5.4% year over year but earnings fell.

The company announced its third-quarter results before the market opened on Tuesday. And there was both good and bad news for investors this time around, too. Here are the highlights of Cantel's Q3 update.

Blue disposable gloves and face mask on a pink surface.

Image source: Getty Images.

By the numbers

Cantel announced Q3 revenue of $228.6 million, up 5.2% from the $217.3 million reported in the same quarter of the previous year. The company's reported revenue was slightly higher than the average analyst revenue estimate of $228.12 million.

How did Cantel's bottom line look in the third quarter? Not so great. The company reported net income of $8.2 million, or $0.20 per share, on GAAP basis. This reflected a 56% year-over-year decline.

Cantel also reported adjusted net income of $23 million, or $0.55 per share, compared to $24.9 million, or $0.60 per share, in the same period in 2018. This narrowly missed the average analysts' earnings estimate of $0.56 per share.

Behind the numbers

It's pretty easy to see why Cantel's revenue grew at a solid clip. Medical sales increased 10.4% year over year to $130.7 million. These gains came largely in the company's U.S. and Asia-Pacific markets. Dental sales growth was even more impressive, with sales jumping 18.5% year over year to $43.6 million. This increase, however, was driven primarily by Cantel's recent acquisition of Omnia.

However, a couple of Cantel's business segments didn't perform so well. Sales for its life sciences segment fell 14% year over year to $46.5 million. The company attributed the decline to "soft capital placements in medical water equipment driven by slower de novo clinic construction." Cantel's dialysis segment sales also slipped 3.7% to $7.7 million primarily due to weakness in Asia-Pacific and Latin American markets.

Cantel's big drop in GAAP earnings was largely related to expenses related to leadership changes during the quarter. The company replaced its CEO during Q1 and made other key executive changes subsequent to the first quarter.

Looking ahead

Cantel projects sales to increase by 5% for full-year 2019. The company thinks that adjusted earnings per share (EPS) will come in between $2.34 and $2.36 -- probably at the lower end of the range.

There are several key things for investors to watch in the coming months. A big one is Cantel's integration efforts with its recent acquisition of Omnia. The company also launched five new products that could help drive growth, including its BHT E series automated endoscope reprocessor (AER). However, new Cantel CEO George Fotiades acknowledged that the company is still facing continued softness in its hemodialysis water business. This could continue to be a significant headwind for Cantel in 2019.


Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cantel Medical Corp. Stock Quote
Cantel Medical Corp.
CMD

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.